Answers are grounded in this paper and cite their sources.
Liver cancer, especially hepatocellular carcinoma (HCC), continues to be a major cause of cancer-related death globally because of its high recurrence rates, tumor heterogeneity, late diagnosis, and resistance to treatment. Systemic toxicity, ineffective targeting, and inconsistent patient response are among the drawbacks of traditional therapeutic approaches. The combination of artificial intelligence (AI) with nanotechnology provides a revolutionary way to address these issues. Through the use of manufactured nanocarriers such liposomes, polymeric nanoparticles, dendrimers, and metal-based nanostructures, nanotechnology allows for accurate medication delivery, improving tumor targeting while reducing off-target effects. At the same time, AI-powered solutions enhance diagnostic precision via multi-omics integration, radiomics, predictive modeling, and sophisticated image analysis, enabling early identification and tailored treatment planning. AI-engineered nanoparticles that target the KRAS and mutant p53 pathways, ferroptosis-inducing nanoplatforms, adaptive drug release systems, and real-time in vivo monitoring techniques are examples of emerging uses. Preclinical results are encouraging, but there are still issues with long-term safety, scalability, regulatory approval, and algorithm interpretability. All things considered, the combination of AI and nanotechnology is a major step toward precision oncology for liver cancer, providing improved diagnostic capabilities, targeted therapy, and individualized treatment plans that could significantly improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Velmurugan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: